Limits...
Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile.

Haas W, Gearinger LS, Usner DW, Decory HH, Morris TW - Clin Ophthalmol (2011)

Bottom Line: Against ciprofloxacin-resistant MRSA and MRSE, besifloxacin was four-fold to ≥ 128-fold more potent than other fluoroquinolones.Patient age and local antibiotic resistance trends should be considered in the treatment of this ocular infection.Besifloxacin showed broad-spectrum in vitro activity and was particularly potent against multidrug-resistant staphylococcal isolates.

View Article: PubMed Central - PubMed

Affiliation: Microbiology and Sterilization Sciences, Bausch and Lomb Inc, Rochester, NY, USA.

ABSTRACT

Background: The purpose of this paper is to report on the bacterial species isolated from patients with bacterial conjunctivitis participating in three clinical trials of besifloxacin ophthalmic suspension, 0.6%, and their in vitro antibacterial susceptibility profiles.

Methods: Microbial data from three clinical studies, conducted at multiple clinical sites in the US and Asia were integrated. Species were identified at a central laboratory, and minimum inhibitory concentrations were determined for various antibiotics, including β-lactams, fluoroquinolones, and macrolides.

Results: A total of 1324 bacterial pathogens representing more than 70 species were isolated. The most common species were Haemophilus influenzae (26.0%), Streptococcus pneumoniae (22.8%), Staphylococcus aureus (14.4%), and Staphylococcus epidermidis (8.4%). H. influenzae was most frequently isolated among patients aged 1-18 years, while S. aureus was most prevalent among those >65 years. Drug resistance was prevalent: Of H. influenzae isolates, 25.3% were β-lactamase positive and 27.2% of S. pneumoniae isolates were penicillin-intermediate/ resistant; of S. aureus isolates, 13.7% were methicillin-resistant (MRSA), and of these, 65.4% were ciprofloxacin-resistant, while 45.9% of S. epidermidis isolates were methicillin-resistant (MRSE), and, of these, 47.1% were ciprofloxacin-resistant. Besifloxacin was more potent than comparator fluoroquinolones overall, and particularly against Gram-positive bacteria. Against ciprofloxacin-resistant MRSA and MRSE, besifloxacin was four-fold to ≥ 128-fold more potent than other fluoroquinolones.

Conclusions: While the pathogen distribution in bacterial conjunctivitis has not changed, drug resistance is increasing. Patient age and local antibiotic resistance trends should be considered in the treatment of this ocular infection. Besifloxacin showed broad-spectrum in vitro activity and was particularly potent against multidrug-resistant staphylococcal isolates.

No MeSH data available.


Related in: MedlinePlus

Distribution of minimum inhibitory concentrations for besifloxacin (light gray) and ciprofloxacin (dark gray) for 825 Gram-positive (A) and 438 Gram-negative isolates from the US (B).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3198410&req=5

f2-opth-5-1369: Distribution of minimum inhibitory concentrations for besifloxacin (light gray) and ciprofloxacin (dark gray) for 825 Gram-positive (A) and 438 Gram-negative isolates from the US (B).

Mentions: Figure 2 shows the MIC distributions for besifloxacin and ciprofloxacin for Gram-positive and Gram-negative isolates obtained from patients at US clinical sites. The 825 Gram-positive isolates among US isolates had MIC50/ MIC90 values of 0.06/0.25 μg/mL for besifloxacin and 0.5/2 μg/mL for ciprofloxacin. Many Gram-positive isolates had ciprofloxacin MICs ≥ 4 μg/mL, reflecting the ciprofloxacin resistance among staphylococcal isolates (discussed further below). The corresponding MIC50/ MIC90 values for the 404 Gram-negative isolates were 0.03/0.25 μg/mL for besifloxacin and 0.015/0.06 μg/mL for ciprofloxacin.


Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile.

Haas W, Gearinger LS, Usner DW, Decory HH, Morris TW - Clin Ophthalmol (2011)

Distribution of minimum inhibitory concentrations for besifloxacin (light gray) and ciprofloxacin (dark gray) for 825 Gram-positive (A) and 438 Gram-negative isolates from the US (B).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3198410&req=5

f2-opth-5-1369: Distribution of minimum inhibitory concentrations for besifloxacin (light gray) and ciprofloxacin (dark gray) for 825 Gram-positive (A) and 438 Gram-negative isolates from the US (B).
Mentions: Figure 2 shows the MIC distributions for besifloxacin and ciprofloxacin for Gram-positive and Gram-negative isolates obtained from patients at US clinical sites. The 825 Gram-positive isolates among US isolates had MIC50/ MIC90 values of 0.06/0.25 μg/mL for besifloxacin and 0.5/2 μg/mL for ciprofloxacin. Many Gram-positive isolates had ciprofloxacin MICs ≥ 4 μg/mL, reflecting the ciprofloxacin resistance among staphylococcal isolates (discussed further below). The corresponding MIC50/ MIC90 values for the 404 Gram-negative isolates were 0.03/0.25 μg/mL for besifloxacin and 0.015/0.06 μg/mL for ciprofloxacin.

Bottom Line: Against ciprofloxacin-resistant MRSA and MRSE, besifloxacin was four-fold to ≥ 128-fold more potent than other fluoroquinolones.Patient age and local antibiotic resistance trends should be considered in the treatment of this ocular infection.Besifloxacin showed broad-spectrum in vitro activity and was particularly potent against multidrug-resistant staphylococcal isolates.

View Article: PubMed Central - PubMed

Affiliation: Microbiology and Sterilization Sciences, Bausch and Lomb Inc, Rochester, NY, USA.

ABSTRACT

Background: The purpose of this paper is to report on the bacterial species isolated from patients with bacterial conjunctivitis participating in three clinical trials of besifloxacin ophthalmic suspension, 0.6%, and their in vitro antibacterial susceptibility profiles.

Methods: Microbial data from three clinical studies, conducted at multiple clinical sites in the US and Asia were integrated. Species were identified at a central laboratory, and minimum inhibitory concentrations were determined for various antibiotics, including β-lactams, fluoroquinolones, and macrolides.

Results: A total of 1324 bacterial pathogens representing more than 70 species were isolated. The most common species were Haemophilus influenzae (26.0%), Streptococcus pneumoniae (22.8%), Staphylococcus aureus (14.4%), and Staphylococcus epidermidis (8.4%). H. influenzae was most frequently isolated among patients aged 1-18 years, while S. aureus was most prevalent among those >65 years. Drug resistance was prevalent: Of H. influenzae isolates, 25.3% were β-lactamase positive and 27.2% of S. pneumoniae isolates were penicillin-intermediate/ resistant; of S. aureus isolates, 13.7% were methicillin-resistant (MRSA), and of these, 65.4% were ciprofloxacin-resistant, while 45.9% of S. epidermidis isolates were methicillin-resistant (MRSE), and, of these, 47.1% were ciprofloxacin-resistant. Besifloxacin was more potent than comparator fluoroquinolones overall, and particularly against Gram-positive bacteria. Against ciprofloxacin-resistant MRSA and MRSE, besifloxacin was four-fold to ≥ 128-fold more potent than other fluoroquinolones.

Conclusions: While the pathogen distribution in bacterial conjunctivitis has not changed, drug resistance is increasing. Patient age and local antibiotic resistance trends should be considered in the treatment of this ocular infection. Besifloxacin showed broad-spectrum in vitro activity and was particularly potent against multidrug-resistant staphylococcal isolates.

No MeSH data available.


Related in: MedlinePlus